Back to List View Graph View

Histone deacetylase 6 (HDAC6)

histone deacetylase 6 (HDAC6) is a cytoplasmic histone deacetylase and a member of the class IIb HDAC family.

Where the papers sit

22 papers from the last 6 months study Histone deacetylase 6 (HDAC6) directly · updated from PubMed 13 Nov 2026

Study type 0 clinical trials · 1 human data · 21 preclinical

Themes 4 themes · 1 new direction

  • Anticancer HDAC6 Inhibitors

    HDAC6 inhibition is being combined with pathway targeting to overcome tumor survival, migration and endocrine resistance. STAT3/HDAC and NQO1/STAT3/HDAC agents, dual PROTAC degraders and niclosamide-based inhibitors recur across breast and other solid tumors. Apoptosis, reactive oxygen species, reduced aggressiveness and tamoxifen resistance are common endpoints. Evidence remains largely preclinical, with selective HDAC6 inhibitors also being tested outside oncology.

    8 papers · 36.4%

  • molecular dynamics

    HDAC6 inhibitor discovery is converging on computationally guided, selective molecules for multiple myeloma and glioblastoma. Molecular docking, dynamics and machine learning are used to prioritize compounds and identify HDAC6 as a therapeutic target. Dual HDAC6/proteasome inhibition is being pursued to intensify apoptosis in myeloma. Activity remains an early preclinical finding, with tumor selectivity and durable efficacy unresolved.

    4 papers · 18.2%

  • Inflammatory Disease Targets

    HDAC6-directed strategies are moving toward dual control of inflammatory signaling in autoimmune and neuroinflammatory disease. cGAS/HDAC and JAK/HDAC inhibitors are being designed to combine immune-pathway suppression with epigenetic regulation, including in psoriasis. HDAC6 inhibition also reduces neuroinflammatory responses after subarachnoid hemorrhage. Selectivity, efficacy and safety across these inflammatory settings remain open questions.

    3 papers · 13.6%

  • Others — Diverse HDAC6 Biology

    HDAC6 inhibition is being explored across leukemia, neurodegeneration, inherited neuropathy, diabetic complications and airway infection. Autophagy disruption, integrated stress responses and immunogenic apoptosis recur in leukemia models. Microtubule stabilization and restored mitochondrial trafficking link HDAC6 to cilia, axonal transport and pathogen entry. PROTAC degradation and selective small-molecule inhibitors remain preclinical approaches rather than a unified therapeutic direction.

    7 papers · 31.8%

NEW DIRECTION

HDAC6 is a reciprocal modification partner in a ciliary-disassembly feedback loop during diabetic complications

Hyperglycemic stress in diabetic retinopathy and nephropathy revealed that HDAC6 is not merely a downstream deacetylase or therapeutic target, as in the inhibitor studies, but a component of a self-reinforcing regulatory complex with PRMT1 at the ciliary basal body. PRMT1 methylated HDAC6 at arginine 16 to increase its stability, while HDAC6 deacetylated PRMT1 at lysine 128 to elevate PRMT1 levels; genetic ablation of either enzyme preserved ciliary architecture and organ function in diabetic mice. This assigns HDAC6 a previously unrepresented role as one half of a reciprocal methylation–deacetylation circuit that stabilizes a pathological pro-disassembly complex, changing the mechanistic interpretation of its contribution to diabetic tissue injury 42691060Sep.

Papers

The 22 papers from the last 6 months that study Histone deacetylase 6 (HDAC6) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Anticancer HDAC6 Inhibitors (8)
  1. Anticancer activity of sodium propionate in hepatocellular carcinoma cells via downregulation of HDAC2 and HDAC6. Journal of computer-aided molecular design · 6 Nov 2026 PMID 42993227
  2. Targeting the DNHD1-HDAC6 axis inactivates prostate cancer cell aggressiveness in vitro, suggesting potential therapeutic vulnerability. Oncology reports · 2 Oct 2026 PMID 42825379
  3. HDAC6 inhibition alleviates dexamethasone-induced skeletal muscle atrophy and enhances UCP3-associated redox homeostasis. Free radical biology & medicine · 5 Aug 2026 PMID 42556488
  4. Design, synthesis, and evaluation of anti-solid-tumor activity of niclosamide-based STAT3/HDAC dual-target inhibitors. Bioorganic chemistry · 29 Jul 2026 PMID 42526131
  5. Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer. Journal of medicinal chemistry · 7 Jul 2026 PMID 42411996
  6. Discovery of novel NQO1/STAT3/HDAC triple-target agents for the treatment of triple negative breast cancer. Bioorganic chemistry · 24 Jun 2026 PMID 42341572
  7. Thiazole-Linked N-Hydroxypropanamide Derivatives: Selective HDAC6 Inhibitors with Therapeutic Potential for Neurodegenerative Diseases. Journal of medicinal chemistry · 4 Jun 2026 PMID 42241502
  8. Development of novel quinoline derivatives as selective HDAC6 inhibitors exhibiting multiple anticancer effects. Bioorganic chemistry · 29 May 2026 PMID 42214832
molecular dynamics (4)
  1. Machine Learning and Molecular Modeling Reveal HDAC6 as a Key Target of Tanshinone IIA in Multiple Myeloma. The journal of physical chemistry. B · 3 Sept 2026 PMID 42691419
  2. Design, synthesis, and biological evaluation of selective HDAC6 inhibitors featuring an N-benzyl-2-(aryl/heteroaryl)acetamide cap. Bioorganic chemistry · 27 Aug 2026 PMID 42660046
  3. Non-covalent dual HDAC6/proteasome inhibitors with anti-multiple myeloma activity. Bioorganic & medicinal chemistry · 13 Aug 2026 PMID 42594764
  4. Synthesis and biological investigation of phenothiazine-based derivatives as potential HDAC6 inhibitors for treatment of glioblastoma multiforme. Bioorganic & medicinal chemistry letters · 6 Jul 2026 PMID 42409124
Inflammatory Disease Targets (3)
  1. Design, Synthesis, and Biological Evaluation of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Psoriasis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018590
  2. HDAC6 inhibition attenuates early brain injury after experimental subarachnoid hemorrhage and suppresses neuroinflammatory responses. Neurochemistry international · 11 Aug 2026 PMID 42580479
  3. Design, Synthesis, and Pharmacological Evaluation of cGAS/HDAC Dual Inhibitors for Treatment of Autoimmune Diseases. Journal of medicinal chemistry · 10 Jun 2026 PMID 42268702
Others — Diverse HDAC6 Biology (7)
  1. Rapid Two-Step Multicomponent Synthesis and Structure-degradation Relationships of Selective HDAC6 PROTAC Degraders. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720482
  2. Imidazo[1,2-a]pyridine-based HDAC6 inhibitor a17 for the treatment of Alzheimer's disease. European journal of pharmacology · 5 Sept 2026 PMID 42700810
  3. Hyperglycemic stress aggravates diabetic retinopathy and nephropathy by promoting cilium disassembly via a deacetylation- and methylation-mediated regulatory mechanism. PLoS biology · 3 Sept 2026 PMID 42691060
  4. HDAC6 inhibition reduces Pseudomonas aeruginosa adherence and internalization in cystic fibrosis epithelial cells via microtubule stabilization. Infection and immunity · 12 Aug 2026 PMID 42584415
  5. HDAC6 inhibition alleviates mitochondrial trafficking in models of Charcot-Marie-Tooth disease type 2A. JCI insight · 14 Jul 2026 PMID 42446926
  6. Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4. Apoptosis : an international journal on programmed cell death · 4 Jul 2026 PMID 42400850
  7. Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 12 Jun 2026 PMID 42284888

By study type

Human data, design not indexed (1)
  1. Anticancer activity of sodium propionate in hepatocellular carcinoma cells via downregulation of HDAC2 and HDAC6. Journal of computer-aided molecular design · 6 Nov 2026 PMID 42993227
Preclinical: animal, cell and lab studies (21)
  1. Design, Synthesis, and Biological Evaluation of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Psoriasis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018590
  2. Targeting the DNHD1-HDAC6 axis inactivates prostate cancer cell aggressiveness in vitro, suggesting potential therapeutic vulnerability. Oncology reports · 2 Oct 2026 PMID 42825379
  3. Rapid Two-Step Multicomponent Synthesis and Structure-degradation Relationships of Selective HDAC6 PROTAC Degraders. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720482
  4. Imidazo[1,2-a]pyridine-based HDAC6 inhibitor a17 for the treatment of Alzheimer's disease. European journal of pharmacology · 5 Sept 2026 PMID 42700810
  5. Machine Learning and Molecular Modeling Reveal HDAC6 as a Key Target of Tanshinone IIA in Multiple Myeloma. The journal of physical chemistry. B · 3 Sept 2026 PMID 42691419
  6. Hyperglycemic stress aggravates diabetic retinopathy and nephropathy by promoting cilium disassembly via a deacetylation- and methylation-mediated regulatory mechanism. PLoS biology · 3 Sept 2026 PMID 42691060
  7. Design, synthesis, and biological evaluation of selective HDAC6 inhibitors featuring an N-benzyl-2-(aryl/heteroaryl)acetamide cap. Bioorganic chemistry · 27 Aug 2026 PMID 42660046
  8. Non-covalent dual HDAC6/proteasome inhibitors with anti-multiple myeloma activity. Bioorganic & medicinal chemistry · 13 Aug 2026 PMID 42594764
  9. HDAC6 inhibition reduces Pseudomonas aeruginosa adherence and internalization in cystic fibrosis epithelial cells via microtubule stabilization. Infection and immunity · 12 Aug 2026 PMID 42584415
  10. HDAC6 inhibition attenuates early brain injury after experimental subarachnoid hemorrhage and suppresses neuroinflammatory responses. Neurochemistry international · 11 Aug 2026 PMID 42580479
  11. HDAC6 inhibition alleviates dexamethasone-induced skeletal muscle atrophy and enhances UCP3-associated redox homeostasis. Free radical biology & medicine · 5 Aug 2026 PMID 42556488
  12. Design, synthesis, and evaluation of anti-solid-tumor activity of niclosamide-based STAT3/HDAC dual-target inhibitors. Bioorganic chemistry · 29 Jul 2026 PMID 42526131
  13. HDAC6 inhibition alleviates mitochondrial trafficking in models of Charcot-Marie-Tooth disease type 2A. JCI insight · 14 Jul 2026 PMID 42446926
  14. Discovery of Effective Dual PROTAC Degraders with Synergistic Antitumor Activity for Overcoming Tamoxifen-Resistant Breast Cancer. Journal of medicinal chemistry · 7 Jul 2026 PMID 42411996
  15. Synthesis and biological investigation of phenothiazine-based derivatives as potential HDAC6 inhibitors for treatment of glioblastoma multiforme. Bioorganic & medicinal chemistry letters · 6 Jul 2026 PMID 42409124
  16. Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4. Apoptosis : an international journal on programmed cell death · 4 Jul 2026 PMID 42400850
  17. Discovery of novel NQO1/STAT3/HDAC triple-target agents for the treatment of triple negative breast cancer. Bioorganic chemistry · 24 Jun 2026 PMID 42341572
  18. Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 12 Jun 2026 PMID 42284888
  19. Design, Synthesis, and Pharmacological Evaluation of cGAS/HDAC Dual Inhibitors for Treatment of Autoimmune Diseases. Journal of medicinal chemistry · 10 Jun 2026 PMID 42268702
  20. Thiazole-Linked N-Hydroxypropanamide Derivatives: Selective HDAC6 Inhibitors with Therapeutic Potential for Neurodegenerative Diseases. Journal of medicinal chemistry · 4 Jun 2026 PMID 42241502
  21. Development of novel quinoline derivatives as selective HDAC6 inhibitors exhibiting multiple anticancer effects. Bioorganic chemistry · 29 May 2026 PMID 42214832